Principal Financial Group’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$527K Buy
7,019
+3,680
+110% +$290K ﹤0.01% 2018
2025
Q4
$264K Sell
3,339
-1,446
-30% -$109K ﹤0.01% 2102
2025
Q3
$313K Sell
4,785
-3,166
-40% -$155K ﹤0.01% 2117
2025
Q2
$314K Sell
7,951
-2,496
-24% -$81.7K ﹤0.01% 2057
2025
Q1
$315K Sell
10,447
-3,169
-23% -$104K ﹤0.01% 1983
2024
Q4
$476K Buy
13,616
+504
+4% +$18.8K ﹤0.01% 1973
2024
Q3
$525K Sell
13,112
-4,346
-25% -$202K ﹤0.01% 1942
2024
Q2
$832K Sell
17,458
-12,366
-41% -$507K ﹤0.01% 1878
2024
Q1
$1.29M Sell
29,824
-1,315
-4% -$62.7K ﹤0.01% 1838
2023
Q4
$1.58M Sell
31,139
-3,512
-10% -$168K ﹤0.01% 1793
2023
Q3
$1.57M Buy
34,651
+1,381
+4% +$57K ﹤0.01% 1795
2023
Q2
$1.37M Sell
33,270
-1,396
-4% -$53.6K ﹤0.01% 1801
2023
Q1
$1.24M Sell
34,666
-3,656
-10% -$137K ﹤0.01% 1829
2022
Q4
$1.45M Sell
38,322
-21,947
-36% -$923K ﹤0.01% 1812
2022
Q3
$2.67M Sell
60,269
-51,899
-46% -$2.19M ﹤0.01% 1669
2022
Q2
$4.15M Buy
112,168
+81,957
+271% +$3.09M ﹤0.01% 1618
2022
Q1
$1.12M Sell
30,211
-1,544
-5% -$50.5K ﹤0.01% 1954
2021
Q4
$966K Sell
31,755
-10,930
-26% -$344K ﹤0.01% 1990
2021
Q3
$1.43M Sell
42,685
-5,285
-11% -$199K ﹤0.01% 1929
2021
Q2
$1.91M Buy
47,970
+3,559
+8% +$139K ﹤0.01% 1924
2021
Q1
$2M Buy
44,411
+3,385
+8% +$189K ﹤0.01% 1854
2020
Q4
$2.32M Sell
41,026
-1,733
-4% -$86.4K ﹤0.01% 1772
2020
Q3
$2.03M Sell
42,759
-2,716
-6% -$151K ﹤0.01% 1735
2020
Q2
$2.68M Buy
45,475
+8,773
+24% +$488K ﹤0.01% 1629
2020
Q1
$1.74M Buy
36,702
+1,244
+4% +$69.3K ﹤0.01% 1633
2019
Q4
$2.14M Sell
35,458
-465
-1% -$27.7K ﹤0.01% 1716
2019
Q3
$2.15M Sell
35,923
-1,458
-4% -$95K ﹤0.01% 1707
2019
Q2
$2.4M Buy
37,381
+928
+3% +$65.6K ﹤0.01% 1700
2019
Q1
$2.96M Buy
36,453
+3,212
+10% +$207K ﹤0.01% 1670
2018
Q4
$1.8M Sell
33,241
-3,667
-10% -$187K ﹤0.01% 1732
2018
Q3
$1.9M Buy
36,908
+1,453
+4% +$68.3K ﹤0.01% 1764
2018
Q2
$1.48M Sell
35,455
-2,822
-7% -$125K ﹤0.01% 1785
2018
Q1
$1.69M Buy
38,277
+1,479
+4% +$75.1K ﹤0.01% 1765
2017
Q4
$1.85M Buy
36,798
+19,754
+116% +$1.08M ﹤0.01% 1765
2017
Q3
$864K Sell
17,044
-4,401
-21% -$231K ﹤0.01% 1848
2017
Q2
$1.09M Buy
21,445
+1,012
+5% +$47.1K ﹤0.01% 1835
2017
Q1
$821K Sell
20,433
-907
-4% -$40.7K ﹤0.01% 1840
2016
Q4
$1.02M Sell
21,340
-3,911
-15% -$155K ﹤0.01% 1812
2016
Q3
$925K Buy
25,251
+380
+2% +$11.9K ﹤0.01% 1787
2016
Q2
$579K Buy
24,871
+2,609
+12% +$84.2K ﹤0.01% 1827
2016
Q1
$902K Buy
22,262
+359
+2% +$14.6K ﹤0.01% 1744
2015
Q4
$1.36M Buy
21,903
+8
+0% +$432 ﹤0.01% 1710
2015
Q3
$885K Buy
21,895
+11,497
+111% +$595K ﹤0.01% 1788
2015
Q2
$598K Sell
10,398
-11,393
-52% -$724K ﹤0.01% 1849
2015
Q1
$1.39M Sell
21,791
-96
-0.4% -$6.51K ﹤0.01% 1716
2014
Q4
$1.35M Sell
21,887
-94
-0.4% -$4.64K ﹤0.01% 1753
2014
Q3
$854K Sell
21,981
-2,458
-10% -$87.1K ﹤0.01% 1782
2014
Q2
$842K Sell
24,439
-10,614
-30% -$334K ﹤0.01% 1812
2014
Q1
$1.51M Sell
35,053
-321
-0.9% -$15.6K ﹤0.01% 1714
2013
Q4
$1.41M Buy
35,374
+44
+0.1% +$1.57K ﹤0.01% 1732
2013
Q3
$1.33M Sell
35,330
-1,972
-5% -$58.9K ﹤0.01% 1711
2013
Q2
$1M Buy
+37,302
New +$793K ﹤0.01% 1726

Other funds holding IONS

Principal Financial Group's IONS Position: Q1 2026 in Review

Principal Financial Group increased its Ionis Pharmaceuticals (IONS) stake by 110% in Q1 2026, buying an estimated $290K and bringing the position to 7,019 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #2018.

Principal Financial Group first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.15M in Q2 2022. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Principal Financial Group held 7,019 shares of Ionis Pharmaceuticals worth $527K as of Q1 2026.
  • Principal Financial Group bought 3,680 Ionis Pharmaceuticals shares in Q1 2026, an estimated $290K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Principal Financial Group's portfolio in Q1 2026, its #2018 holding.
  • Principal Financial Group first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Principal Financial Group's Ionis Pharmaceuticals position peaked at $4.15M in Q2 2022.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.